SLC16A3 and pancreatic adenocarcinoma: Based on the acquired data, it can be said with some degree of confidence that SLC16A3 may function as a risk factor for patients with PAAD, CESC, LUSC, LUAD, CHOL, LGG, MESO, and OSCC (Fig. 6).